Erin BellSenior Commercial Counsel at Zealand Pharma
Erin is currently at Zealand Pharma US, Inc. where she supports the needs of the US Commercial organization in all aspects of its first launched product, Zegalogue. Before Zealand, Erin was at Pear Therapeutics, Inc., a digital health company, where she served as Assistant General Counsel. At Pear, Erin participated in the launch of Somryst, the company’s third FDA-approved product and helped build Pear’s Compliance Program. Prior to joining Pear, Erin was Senior Counsel at Sunovion Pharmaceuticals, Inc. and acted as legal brand lead for Latuda, a drug that ultimately achieved blockbuster status. At Sunovion, Erin was also part of the litigation team that secured four additional years of patent exclusivity in the market for Latuda. Prior to Sunovion, Erin worked at PerkinElmer, a medical device company, where she provided counsel to several of the company’s subsidiaries. Erin earned her BS from Clark University and her JD from Suffolk University School of Law.